Health
Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%
By Marcus Chen
KFGO
Advertisement
Moderna and Merck are expected to share the Phase 3 data for their experimental cancer vaccine this weekend at a medical conference.